Our data demonstrated that mutational activation of KRAS robustly promoted BCL6 expression (Figure 1), and genetic depletion of BCL6 exhibited a profound inhibitory effect on KRAS-driven lung tumorigenesis (Figure 6), suggesting that BCL6 is a lynchpin for oncogenic KRAS dependence in lung cancer. The gene discussed is KRAS; the disease is lung carcinoma.